{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T01:37:43Z","timestamp":1787017063450,"version":"build-2736575974"},"reference-count":151,"publisher":"BMJ","issue":"5","license":[{"start":{"date-parts":[[2021,5,13]],"date-time":"2021-05-13T00:00:00Z","timestamp":1620864000000},"content-version":"unspecified","delay-in-days":12,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2021,4,15]]},"published-print":{"date-parts":[[2021,5]]},"abstract":"<jats:p>COVID-19, the syndrome caused by the infection with SARS-CoV-2 coronavirus, is characterized, in its severe form, by interstitial diffuse pneumonitis and acute respiratory distress syndrome (ARDS). ARDS and systemic manifestations of COVID-19 are mainly due to an exaggerated immune response triggered by the viral infection. Cytokine release syndrome (CRS), an inflammatory syndrome characterized by elevated levels of circulating cytokines, and endothelial dysfunction are systemic manifestations of COVID-19. CRS is also an adverse event of immunotherapy (IMTX), the treatment of diseases using drugs, cells, and antibodies to stimulate or suppress the immune system. Graft-versus-host disease complications after an allogeneic stem cell transplant, toxicity after the infusion of chimeric antigen receptor-T cell therapy and monoclonal antibodies can all lead to CRS. It is hypothesized that anti-inflammatory drugs used for treatment of CRS in IMTX may be useful in reducing the mortality in COVID-19, whereas IMTX itself may help in ameliorating effects of SARS-CoV-2 infection. In this paper, we focused on the potential shared mechanisms and differences between COVID-19 and IMTX-related toxicities. We performed a systematic review of the clinical trials testing anti-inflammatory therapies and of the data published from prospective trials. Preliminary evidence suggests there might be a benefit in targeting the cytokines involved in the pathogenesis of COVID-19, especially by inhibiting the interleukin-6 pathway. Many other approaches based on novel drugs and cell therapies are currently under investigation and may lead to a reduction in hospitalization and mortality due to COVID-19.<\/jats:p>","DOI":"10.1136\/jitc-2021-002392","type":"journal-article","created":{"date-parts":[[2021,5,13]],"date-time":"2021-05-13T13:07:46Z","timestamp":1620911266000},"page":"e002392","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":15,"title":["Shared inflammatory pathways and therapeutic strategies in COVID-19 and cancer immunotherapy"],"prefix":"10.1136","volume":"9","clinical-trial-number":[{"clinical-trial-number":"nct04365101","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3165-1899","authenticated-orcid":false,"given":"Lorenzo","family":"Iovino","sequence":"first","affiliation":[{"name":"Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurel A","family":"Thur","sequence":"additional","affiliation":[{"name":"Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sacha","family":"Gnjatic","sequence":"additional","affiliation":[{"name":"Medicine\u2014Hematology\/Oncology, Icahn School of Medicine at Mount Sinai, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aude","family":"Chapuis","sequence":"additional","affiliation":[{"name":"Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA"},{"name":"Department of Medicine, University of Washington, Seattle, Washington, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filippo","family":"Milano","sequence":"additional","affiliation":[{"name":"Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA"},{"name":"Department of Medicine, University of Washington, Seattle, Washington, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua A","family":"Hill","sequence":"additional","affiliation":[{"name":"Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA"},{"name":"Department of Medicine, University of Washington, Seattle, Washington, USA"},{"name":"Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2021,5,13]]},"reference":[{"key":"2025100314291469000_9.5.e002392.1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(20)30120-1"},{"key":"2025100314291469000_9.5.e002392.2","doi-asserted-by":"crossref","unstructured":"Zheng KI , Feng G , Liu WY . Extrapulmonary complications of COVID-19: a multisystem disease? J Med Virol 2020.","DOI":"10.1002\/jmv.26294"},{"key":"2025100314291469000_9.5.e002392.3","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.1002\/jmv.26595","article-title":"Extrapulmonary manifestations of severe acute respiratory syndrome coronavirus-2 infection","volume":"93","author":"Rosen","year":"2021","journal-title":"J Med Virol"},{"key":"2025100314291469000_9.5.e002392.4","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1038\/s41591-020-1051-9","article-title":"An inflammatory cytokine signature predicts COVID-19 severity and survival","volume":"26","author":"Del Valle","year":"2020","journal-title":"Nat Med"},{"key":"2025100314291469000_9.5.e002392.5","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1038\/s41577-020-0306-5","article-title":"A guide to cancer immunotherapy: from T cell basic science to clinical practice","volume":"20","author":"Waldman","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"2025100314291469000_9.5.e002392.6","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(16)00078-5"},{"key":"2025100314291469000_9.5.e002392.7","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s13054-017-1678-1","article-title":"New drugs, new toxicities: severe side effects of modern targeted and immunotherapy of cancer and their management","volume":"21","author":"Kroschinsky","year":"2017","journal-title":"Critical Care"},{"key":"2025100314291469000_9.5.e002392.8","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2019.01529","article-title":"Controlling cytokine release syndrome to harness the full potential of CAR-Based cellular therapy","volume":"9","author":"Thakar","year":"2019","journal-title":"Front Oncol"},{"key":"2025100314291469000_9.5.e002392.9","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2003138117"},{"key":"2025100314291469000_9.5.e002392.10","doi-asserted-by":"crossref","unstructured":"Quan C , Li C , Ma H , et al . Immunopathogenesis of coronavirus-induced acute respiratory distress syndrome (ARDS): potential infection-associated hemophagocytic lymphohistiocytosis. Clin Microbiol Rev 2020;34.doi:10.1128\/CMR.00074-20","DOI":"10.1128\/CMR.00074-20"},{"key":"2025100314291469000_9.5.e002392.11","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.12839.e4"},{"key":"2025100314291469000_9.5.e002392.12","doi-asserted-by":"publisher","DOI":"10.1016\/SO140-6736(20)30566-3"},{"key":"2025100314291469000_9.5.e002392.13","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0235653","article-title":"Rate of intensive care unit admission and outcomes among patients with coronavirus: a systematic review and meta-analysis","volume":"15","author":"Abate","year":"2020","journal-title":"PLoS One"},{"key":"2025100314291469000_9.5.e002392.14","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/S2213-2600(20)30079-5","article-title":"Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study","volume":"8","author":"Yang","year":"2020","journal-title":"The Lancet Respiratory Medicine"},{"key":"2025100314291469000_9.5.e002392.15","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1056\/NEJMoa2015432","article-title":"Pulmonary vascular Endothelialitis, thrombosis, and angiogenesis in Covid-19","volume":"383","author":"Ackermann","year":"2020","journal-title":"N Engl J Med Overseas Ed"},{"key":"2025100314291469000_9.5.e002392.16","doi-asserted-by":"publisher","DOI":"10.1038\/s12276-018-0116-z"},{"key":"2025100314291469000_9.5.e002392.17","doi-asserted-by":"crossref","DOI":"10.1186\/s12890-018-0592-x","article-title":"High incidence and early onset of nivolumab-induced pneumonitis: four case reports and literature review","volume":"18","author":"Koyama","year":"2018","journal-title":"BMC Pulm Med"},{"key":"2025100314291469000_9.5.e002392.18","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-1040"},{"key":"2025100314291469000_9.5.e002392.19","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-18-0243"},{"key":"2025100314291469000_9.5.e002392.20","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2021.e06187","article-title":"SARS-CoV-2 spike protein S1 subunit induces pro-inflammatory responses via Toll-like receptor 4 signaling in murine and human macrophages","volume":"7","author":"Shirato","year":"2021","journal-title":"Heliyon"},{"key":"2025100314291469000_9.5.e002392.21","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.3390\/cells9112392","article-title":"Hyperthrombotic milieu in COVID-19 patients","volume":"9","author":"Kamel","year":"2020","journal-title":"Cells"},{"key":"2025100314291469000_9.5.e002392.22","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2020.100745","article-title":"Coagulation dysfunction in COVID-19: the interplay between inflammation, viral infection and the coagulation system","volume":"46","author":"Lazzaroni","year":"2021","journal-title":"Blood Rev"},{"key":"2025100314291469000_9.5.e002392.23","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1002\/jmv.26306","article-title":"Clinical characteristics and predictors of mortality in African-Americans with COVID-19 from an inner-city community teaching hospital in New York","volume":"93","author":"Gayam","year":"2021","journal-title":"J Med Virol"},{"key":"2025100314291469000_9.5.e002392.24","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.thromres.2020.07.047","article-title":"D-Dimer level is associated with the severity of COVID-19","volume":"195","author":"Yu","year":"2020","journal-title":"Thromb Res"},{"key":"2025100314291469000_9.5.e002392.25","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020006000"},{"key":"2025100314291469000_9.5.e002392.26","doi-asserted-by":"crossref","unstructured":"Elgendy IY , Kolte D , Mansour MK . Incidence, predictors, and outcomes of thrombotic events in hospitalized patients with viral pneumonia. Am J Cardiol 2021.","DOI":"10.1016\/j.amjcard.2021.01.001"},{"key":"2025100314291469000_9.5.e002392.27","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1007\/s00134-020-06088-1","article-title":"Understanding pathophysiology of hemostasis disorders in critically ill patients with COVID-19","volume":"46","author":"Joly","year":"2020","journal-title":"Intensive Care Med"},{"key":"2025100314291469000_9.5.e002392.28","first-page":"3950","article-title":"COVID-19, microangiopathy, hemostatic activation, and complement","volume":"130","author":"Song","year":"2020","journal-title":"J Clin Invest"},{"key":"2025100314291469000_9.5.e002392.29","doi-asserted-by":"crossref","first-page":"5674","DOI":"10.1172\/JCI142780","article-title":"Complement and coagulation: key triggers of COVID-19\u2013induced multiorgan pathology","volume":"130","author":"Ghebrehiwet","year":"2020","journal-title":"J Clin Invest"},{"key":"2025100314291469000_9.5.e002392.30","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1161\/CIRCULATIONAHA.120.047430","article-title":"Pulmonary embolism in patients with COVID-19: awareness of an increased prevalence","volume":"142","author":"Poissy","year":"2020","journal-title":"Circulation"},{"key":"2025100314291469000_9.5.e002392.31","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-0968-3"},{"key":"2025100314291469000_9.5.e002392.32","doi-asserted-by":"publisher","DOI":"10.1002\/path.1570"},{"key":"2025100314291469000_9.5.e002392.33","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21218081"},{"key":"2025100314291469000_9.5.e002392.34","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20201012","article-title":"Neutrophil extracellular traps infiltrate the lung airway, interstitial, and vascular compartments in severe COVID-19","volume":"217","author":"Radermecker","year":"2020","journal-title":"J Exp Med"},{"key":"2025100314291469000_9.5.e002392.35","article-title":"COVID-19 cytokines and the hyperactive immune response: synergism of TNF-\u03b1 and IFN-\u03b3 in triggering inflammation, tissue damage, and death","author":"Karki","year":"2020","journal-title":"bioRxiv"},{"key":"2025100314291469000_9.5.e002392.36","doi-asserted-by":"crossref","first-page":"2444","DOI":"10.1016\/j.ajem.2020.09.054","article-title":"Non-Respiratory presentations of COVID-19, a clinical review","volume":"38","author":"AlSamman","year":"2020","journal-title":"Am J Emerg Med"},{"key":"2025100314291469000_9.5.e002392.37","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-020-00954-7"},{"key":"2025100314291469000_9.5.e002392.38","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-06-793141"},{"key":"2025100314291469000_9.5.e002392.39","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1008737","article-title":"Interplay between SARS-CoV-2 and the type I interferon response","volume":"16","author":"Sa Ribero","year":"2020","journal-title":"PLoS Pathog"},{"key":"2025100314291469000_9.5.e002392.40","article-title":"Structure of SARS-CoV-2 ORF8, a rapidly evolving coronavirus protein implicated in immune evasion","author":"Flower","year":"2020","journal-title":"bioRxiv"},{"key":"2025100314291469000_9.5.e002392.41","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmcr.2020.101162"},{"key":"2025100314291469000_9.5.e002392.42","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1016\/j.bbmt.2019.07.027","article-title":"Severe cytokine release syndrome after haploidentical peripheral blood stem cell transplantation","volume":"25","author":"Imus","year":"2019","journal-title":"Biology of Blood and Marrow Transplantation"},{"key":"2025100314291469000_9.5.e002392.43","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1111\/bjh.16190","article-title":"Advances in understanding the pathogenesis of graft-versus-host disease","volume":"187","author":"Zeiser","year":"2019","journal-title":"Br J Haematol"},{"key":"2025100314291469000_9.5.e002392.44","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-08-551994"},{"key":"2025100314291469000_9.5.e002392.45","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/s41409-019-0637-7","article-title":"Haemophagocytic lymphohistiocytosis (HLH) following allogeneic haematopoietic stem cell transplantation (HSCT)-time to reappraise with modern diagnostic and treatment strategies?","volume":"55","author":"Sandler","year":"2020","journal-title":"Bone Marrow Transplant"},{"key":"2025100314291469000_9.5.e002392.46","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.bbmt.2017.10.035","article-title":"Cellular immunotherapy for hematologic malignancies: beyond bone marrow transplantation","volume":"24","author":"Cirillo","year":"2018","journal-title":"Biology of Blood and Marrow Transplantation"},{"key":"2025100314291469000_9.5.e002392.47","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.blre.2018.11.002","article-title":"Recent advances in car T-cell toxicity: mechanisms, manifestations and management","volume":"34","author":"Brudno","year":"2019","journal-title":"Blood Rev"},{"key":"2025100314291469000_9.5.e002392.48","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.12.756"},{"key":"2025100314291469000_9.5.e002392.49","doi-asserted-by":"publisher","DOI":"10.1038\/nrd3003"},{"key":"2025100314291469000_9.5.e002392.50","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2018.1.25"},{"key":"2025100314291469000_9.5.e002392.51","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1016\/S2213-2600(20)30404-5","article-title":"Cytokine elevation in severe and critical COVID-19: a rapid systematic review, meta-analysis, and comparison with other inflammatory syndromes","volume":"8","author":"Leisman","year":"2020","journal-title":"The Lancet Respiratory Medicine"},{"key":"2025100314291469000_9.5.e002392.52","doi-asserted-by":"publisher","DOI":"10.1136\/gut.36.1.45"},{"key":"2025100314291469000_9.5.e002392.53","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/s41584-020-0419-z","article-title":"Translating IL-6 biology into effective treatments","volume":"16","author":"Choy","year":"2020","journal-title":"Nat Rev Rheumatol"},{"key":"2025100314291469000_9.5.e002392.54","doi-asserted-by":"publisher","DOI":"10.1038\/ni.3153"},{"key":"2025100314291469000_9.5.e002392.55","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.jaci.2020.07.001","article-title":"The role of IL-6 and other mediators in the cytokine storm associated with SARS-CoV-2 infection","volume":"146","author":"Copaescu","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"2025100314291469000_9.5.e002392.56","doi-asserted-by":"crossref","DOI":"10.1007\/s11912-019-0789-z","article-title":"Chimeric antigen Receptor-Engineered T cell therapy in lymphoma","volume":"21","author":"Strati","year":"2019","journal-title":"Curr Oncol Rep"},{"key":"2025100314291469000_9.5.e002392.57","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-01-400515"},{"key":"2025100314291469000_9.5.e002392.58","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/s00251-020-01179-1","article-title":"Elevated interleukin-6 and adverse outcomes in COVID-19 patients: a meta-analysis based on adjusted effect estimates","volume":"72","author":"Zhang","year":"2020","journal-title":"Immunogenetics"},{"key":"2025100314291469000_9.5.e002392.59","doi-asserted-by":"crossref","first-page":"2003006","DOI":"10.1183\/13993003.03006-2020","article-title":"Confronting the controversy: interleukin-6 and the COVID-19 cytokine storm syndrome","volume":"56","author":"Chen","year":"2020","journal-title":"Eur Respir J"},{"key":"2025100314291469000_9.5.e002392.60","article-title":"COVID-19 cytokines and the hyperactive immune response: synergism of TNF-\u03b1 and IFN-\u03b3 in triggering inflammation, tissue damage, and death","author":"Karki","year":"2020","journal-title":"bioRxiv"},{"key":"2025100314291469000_9.5.e002392.61","doi-asserted-by":"crossref","DOI":"10.1002\/jcla.23618","article-title":"Ferritin in the coronavirus disease 2019 (COVID\u201019): a systematic review and meta\u2010analysis","volume":"34","author":"Cheng","year":"2020","journal-title":"J Clin Lab Anal"},{"key":"2025100314291469000_9.5.e002392.62","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(20)30221-0"},{"key":"2025100314291469000_9.5.e002392.63","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1001\/jamaneurol.2020.1127","article-title":"Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China","volume":"77","author":"Mao","year":"2020","journal-title":"JAMA Neurol"},{"key":"2025100314291469000_9.5.e002392.64","doi-asserted-by":"crossref","DOI":"10.1007\/s11910-020-01079-7","article-title":"Central nervous system manifestations associated with COVID-19","volume":"20","author":"Divani","year":"2020","journal-title":"Curr Neurol Neurosci Rep"},{"key":"2025100314291469000_9.5.e002392.65","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/S2215-0366(20)30287-X","article-title":"Neurological and neuropsychiatric complications of COVID-19 in 153 patients: a UK-wide surveillance study","volume":"7","author":"Varatharaj","year":"2020","journal-title":"Lancet Psychiatry"},{"key":"2025100314291469000_9.5.e002392.66","doi-asserted-by":"publisher","DOI":"10.3390\/cells9112360"},{"key":"2025100314291469000_9.5.e002392.67","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-020-01896-0"},{"key":"2025100314291469000_9.5.e002392.68","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2020.102535"},{"key":"2025100314291469000_9.5.e002392.69","doi-asserted-by":"crossref","first-page":"S42","DOI":"10.1002\/ajh.25445","article-title":"Toxicities of CD19 CAR\u2010T cell immunotherapy","volume":"94","author":"Hirayama","year":"2019","journal-title":"Am J Hematol"},{"key":"2025100314291469000_9.5.e002392.70","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2017.148"},{"key":"2025100314291469000_9.5.e002392.71","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-17-0698"},{"key":"2025100314291469000_9.5.e002392.72","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1097\/MCG.0000000000001432","article-title":"Hepatic injury in patients with COVID-19","volume":"54","author":"Kullar","year":"2020","journal-title":"J Clin Gastroenterol"},{"key":"2025100314291469000_9.5.e002392.73","doi-asserted-by":"crossref","unstructured":"Barbosa da Luz B , de Oliveira NMT , Fran\u00e7a Dos Santos IW . An overview of the gut side of the SARS-CoV-2 infection. Intestinal research 2020.","DOI":"10.5217\/ir.2020.00087"},{"key":"2025100314291469000_9.5.e002392.74","article-title":"Digestive system manifestations and clinical significance of coronavirus disease 2019: a systematic literature review","author":"Ye","year":"2020","journal-title":"J Gastroenterol Hepatol"},{"key":"2025100314291469000_9.5.e002392.75","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21176351","article-title":"Natural killer cell dysfunction and its role in COVID-19","volume":"21","author":"van Eeden","year":"2020","journal-title":"Int J Mol Sci"},{"key":"2025100314291469000_9.5.e002392.76","doi-asserted-by":"crossref","DOI":"10.1210\/jendso\/bvaa144","article-title":"SARS-CoV-2 (COVID-19) and the endocrine system","volume":"4","author":"Lundholm","year":"2020","journal-title":"J Endocr Soc"},{"key":"2025100314291469000_9.5.e002392.77","article-title":"COVID-19: infection or autoimmunity","volume":"2020","author":"Icenogle","year":"2055","journal-title":"Frontiers in immunology"},{"key":"2025100314291469000_9.5.e002392.78","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0000000000002888"},{"key":"2025100314291469000_9.5.e002392.79","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020008488"},{"key":"2025100314291469000_9.5.e002392.80","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.02250","article-title":"Engineered T cell therapy for cancer in the clinic","volume":"10","author":"Zhao","year":"2019","journal-title":"Front Immunol"},{"key":"2025100314291469000_9.5.e002392.81","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-019-0472-9"},{"key":"2025100314291469000_9.5.e002392.82","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/s41392-019-0070-9","article-title":"Genetically engineered T cells for cancer immunotherapy","volume":"4","author":"Li","year":"2019","journal-title":"Sig Transduct Target Ther"},{"key":"2025100314291469000_9.5.e002392.83","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.RA118.007187"},{"key":"2025100314291469000_9.5.e002392.84","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-09-077438"},{"key":"2025100314291469000_9.5.e002392.85","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1016\/j.bbmt.2016.04.009","article-title":"Haploidentical natural killer cells infused before allogeneic stem cell transplantation for myeloid malignancies: a phase I trial","volume":"22","author":"Lee","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"2025100314291469000_9.5.e002392.86","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1910607"},{"key":"2025100314291469000_9.5.e002392.87","article-title":"Efficacy of targeting SARS-CoV-2 by CAR-NK cells","author":"Ma","year":"2020","journal-title":"bioRxiv"},{"key":"2025100314291469000_9.5.e002392.88","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.580237"},{"key":"2025100314291469000_9.5.e002392.89","doi-asserted-by":"crossref","first-page":"6781","DOI":"10.18632\/oncotarget.27285","article-title":"Mesangiogenic progenitor cells are forced toward the angiogenic fate, in multiple myeloma","volume":"10","author":"Pacini","year":"2019","journal-title":"Oncotarget"},{"key":"2025100314291469000_9.5.e002392.90","doi-asserted-by":"crossref","unstructured":"Rambaldi B , Diral E , Donsante S . Heterogeneity of the bone marrow niche in patients with myeloproliferative neoplasms: ActivinA secretion by mesenchymal stromal cells correlates with the degree of marrow fibrosis. Ann Hematol 2020.","DOI":"10.1007\/s00277-020-04306-w"},{"key":"2025100314291469000_9.5.e002392.91","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/s41536-019-0083-6","article-title":"Mesenchymal stem cell perspective: cell biology to clinical progress","volume":"4","author":"Pittenger","year":"2019","journal-title":"NPJ Regen Med"},{"key":"2025100314291469000_9.5.e002392.92","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-11-785865"},{"key":"2025100314291469000_9.5.e002392.93","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1089\/scd.2010.0095","article-title":"Efficacy assessment of Interferon-Alpha\u2013Engineered mesenchymal stromal cells in a mouse plasmacytoma model","volume":"20","author":"Sartoris","year":"2011","journal-title":"Stem Cells Dev"},{"key":"2025100314291469000_9.5.e002392.94","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1016\/j.bbmt.2014.06.015","article-title":"Sequential Third-Party Mesenchymal Stromal Cell Therapy for Refractory Acute Graft-versus-Host Disease","volume":"20","author":"S\u00e1nchez-Guijo","year":"2014","journal-title":"Biology of Blood and Marrow Transplantation"},{"key":"2025100314291469000_9.5.e002392.95","doi-asserted-by":"publisher","DOI":"10.1186\/s13287-020-01875-5"},{"key":"2025100314291469000_9.5.e002392.96","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1038\/s41392-020-00286-5","article-title":"Human umbilical cord-derived mesenchymal stem cell therapy in patients with COVID-19: a phase 1 clinical trial","volume":"5","author":"Meng","year":"2020","journal-title":"Signal Transduction and Targeted Therapy"},{"key":"2025100314291469000_9.5.e002392.97","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1089\/scd.2020.0080","article-title":"Exosomes derived from bone marrow mesenchymal stem cells as treatment for severe COVID-19","volume":"29","author":"Sengupta","year":"2020","journal-title":"Stem Cells Dev"},{"key":"2025100314291469000_9.5.e002392.98","unstructured":"Anderson EJ , Rouphael NG , Widge AT . Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults. N Engl J Med 2020."},{"key":"2025100314291469000_9.5.e002392.99","doi-asserted-by":"crossref","unstructured":"Baden LR , El Sahly HM , Essink B . Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med 2020.","DOI":"10.1056\/NEJMoa2035389"},{"key":"2025100314291469000_9.5.e002392.100","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2034577"},{"key":"2025100314291469000_9.5.e002392.101","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32661-1"},{"key":"2025100314291469000_9.5.e002392.102","doi-asserted-by":"crossref","unstructured":"Sadoff J , Le Gars M , Shukarev G , et al . Interim results of a phase 1\u20132a trial of Ad26.COV2.S Covid-19 vaccine. N Engl J Med Overseas Ed 2021.doi:10.1056\/NEJMoa2034201","DOI":"10.1056\/NEJMoa2034201"},{"key":"2025100314291469000_9.5.e002392.103","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-1088-9"},{"key":"2025100314291469000_9.5.e002392.104","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1056\/NEJMoa2033700","article-title":"Early high-titer plasma therapy to prevent severe Covid-19 in older adults","volume":"384","author":"Libster","year":"2021","journal-title":"N Engl J Med"},{"key":"2025100314291469000_9.5.e002392.105","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1056\/NEJMoa2031304","article-title":"A randomized trial of convalescent plasma in Covid-19 severe pneumonia","volume":"384","author":"Simonovich","year":"2021","journal-title":"N Engl J Med"},{"key":"2025100314291469000_9.5.e002392.106","doi-asserted-by":"crossref","unstructured":"Crawford KHD , Dingens AS , Eguia R . Dynamics of neutralizing antibody titers in the months after SARS-CoV-2 infection. J Infect Dis 2020.","DOI":"10.1101\/2020.08.06.20169367"},{"key":"2025100314291469000_9.5.e002392.107","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-020-0311-8"},{"key":"2025100314291469000_9.5.e002392.108","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1111\/1756-185X.13220","article-title":"Role of intravenous immunoglobulin in the treatment of Kawasaki disease","volume":"21","author":"Lo","year":"2018","journal-title":"Int J Rheum Dis"},{"key":"2025100314291469000_9.5.e002392.109","first-page":"726","article-title":"Antiviral agents, glucocorticoids, antibiotics, and intravenous immunoglobulin in 1142 patients with coronavirus disease 2019: a systematic review and meta-analysis","volume":"130","author":"Pei","year":"2020","journal-title":"Pol Arch Intern Med"},{"key":"2025100314291469000_9.5.e002392.110","doi-asserted-by":"crossref","first-page":"107","DOI":"10.12688\/wellcomeopenres.15987.2","article-title":"COVID-19 and Guillain-Barre syndrome: a systematic review of case reports","volume":"5","author":"Carrillo-Larco","year":"2020","journal-title":"Wellcome Open Res"},{"key":"2025100314291469000_9.5.e002392.111","doi-asserted-by":"publisher","DOI":"10.1126\/science.abc6952"},{"key":"2025100314291469000_9.5.e002392.112","doi-asserted-by":"publisher","DOI":"10.1126\/science.abe2402"},{"key":"2025100314291469000_9.5.e002392.113","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2012.04.005"},{"key":"2025100314291469000_9.5.e002392.114","doi-asserted-by":"crossref","first-page":"83","DOI":"10.4037\/ccn2020588","article-title":"Corticosteroids for treating sepsis in children and adults","volume":"40","author":"Cooper","year":"2020","journal-title":"Crit Care Nurse"},{"key":"2025100314291469000_9.5.e002392.115","unstructured":"Horby P , Lim WS . et al. Dexamethasone in Hospitalized Patients with Covid-19 - Preliminary Report. N Engl J Med 2020."},{"key":"2025100314291469000_9.5.e002392.116","doi-asserted-by":"crossref","DOI":"10.1186\/s13063-020-04641-3","article-title":"Corticosteroid therapy for critically ill patients with COVID-19: a structured summary of a study protocol for a prospective meta-analysis of randomized trials","volume":"21","author":"Sterne","year":"2020","journal-title":"Trials"},{"key":"2025100314291469000_9.5.e002392.117","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1038\/s41409-020-0855-z","article-title":"Treatment of steroid resistant acute graft versus host disease with an anti-CD26 monoclonal antibody-Begelomab","volume":"55","author":"Bacigalupo","year":"2020","journal-title":"Bone Marrow Transplant"},{"key":"2025100314291469000_9.5.e002392.118","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-017-0829-7"},{"key":"2025100314291469000_9.5.e002392.119","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709866"},{"key":"2025100314291469000_9.5.e002392.120","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.25801"},{"key":"2025100314291469000_9.5.e002392.121","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2005615117"},{"key":"2025100314291469000_9.5.e002392.122","doi-asserted-by":"crossref","first-page":"e474","DOI":"10.1016\/S2665-9913(20)30173-9","article-title":"Tocilizumab in patients with severe COVID-19: a retrospective cohort study","volume":"2","author":"Guaraldi","year":"2020","journal-title":"Lancet Rheumatol"},{"key":"2025100314291469000_9.5.e002392.123","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1056\/NEJMoa2028836","article-title":"Efficacy of tocilizumab in patients hospitalized with Covid-19","volume":"383","author":"Stone","year":"2020","journal-title":"N Engl J Med Overseas Ed"},{"key":"2025100314291469000_9.5.e002392.124","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1001\/jamainternmed.2020.6615","article-title":"Effect of tocilizumab vs standard care on clinical worsening in patients hospitalized with COVID-19 pneumonia: a randomized clinical trial","volume":"181","author":"Salvarani","year":"2021","journal-title":"JAMA Intern Med"},{"key":"2025100314291469000_9.5.e002392.125","doi-asserted-by":"crossref","DOI":"10.1001\/jamainternmed.2020.6820","article-title":"Effect of tocilizumab vs usual care in adults hospitalized with COVID-19 and moderate or severe pneumonia: a randomized clinical trial","volume":"181","author":"Hermine","year":"2021","journal-title":"JAMA Intern Med"},{"key":"2025100314291469000_9.5.e002392.126","doi-asserted-by":"crossref","DOI":"10.1001\/jamainternmed.2020.6252","article-title":"Association between early treatment with tocilizumab and mortality among critically ill patients with COVID-19","volume":"181","author":"Gupta","year":"2021","journal-title":"JAMA Intern Med"},{"key":"2025100314291469000_9.5.e002392.127","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2028700","article-title":"Tocilizumab in hospitalized patients with severe Covid-19 pneumonia","author":"Rosas","year":"2021","journal-title":"N Engl J Med"},{"key":"2025100314291469000_9.5.e002392.128","doi-asserted-by":"crossref","DOI":"10.1016\/S2213-2600(21)00099-0","article-title":"Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial","author":"Lescure","year":"2021","journal-title":"Lancet Respir Med"},{"key":"2025100314291469000_9.5.e002392.129","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.31.8907"},{"key":"2025100314291469000_9.5.e002392.130","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-12-013748"},{"key":"2025100314291469000_9.5.e002392.131","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1056\/NEJMoa1917635","article-title":"Ruxolitinib for Glucocorticoid-Refractory acute graft-versus-host disease","volume":"382","author":"Zeiser","year":"2020","journal-title":"N Engl J Med"},{"key":"2025100314291469000_9.5.e002392.132","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1038\/s41375-020-0891-0","article-title":"The Janus kinase 1\/2 inhibitor ruxolitinib in COVID-19 with severe systemic hyperinflammation","volume":"34","author":"La Ros\u00e9e","year":"2020","journal-title":"Leukemia"},{"key":"2025100314291469000_9.5.e002392.133","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2007764"},{"key":"2025100314291469000_9.5.e002392.134","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1056\/NEJMoa2031994","article-title":"Baricitinib plus Remdesivir for hospitalized adults with Covid-19","volume":"384","author":"Kalil","year":"2021","journal-title":"N Engl J Med"},{"key":"2025100314291469000_9.5.e002392.135","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.090074"},{"key":"2025100314291469000_9.5.e002392.136","doi-asserted-by":"crossref","first-page":"e393","DOI":"10.1016\/S2665-9913(20)30164-8","article-title":"Anakinra for severe forms of COVID-19: a cohort study","volume":"2","author":"Huet","year":"2020","journal-title":"Lancet Rheumatol"},{"key":"2025100314291469000_9.5.e002392.137","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1056\/NEJMoa1911326","article-title":"Emapalumab in children with primary hemophagocytic lymphohistiocytosis","volume":"382","author":"Locatelli","year":"2020","journal-title":"N Engl J Med"},{"key":"2025100314291469000_9.5.e002392.138","doi-asserted-by":"publisher","DOI":"10.1186\/s13054-020-03158-0"},{"key":"2025100314291469000_9.5.e002392.139","doi-asserted-by":"crossref","first-page":"e779","DOI":"10.1016\/S2665-9913(20)30340-4","article-title":"Imperfect storm: is interleukin-33 the Achilles heel of COVID-19?","volume":"2","author":"Zizzo","year":"2020","journal-title":"Lancet Rheumatol"},{"key":"2025100314291469000_9.5.e002392.140","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.16485","article-title":"Association of interleukin 7 immunotherapy with lymphocyte counts among patients with severe coronavirus disease 2019 (COVID-19)","volume":"3","author":"Laterre","year":"2020","journal-title":"JAMA Netw Open"},{"key":"2025100314291469000_9.5.e002392.141","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1111\/bjh.16557","article-title":"Modified diagnostic criteria, grading classification and newly elucidated pathophysiology of hepatic SOS\/VOD after haematopoietic cell transplantation","volume":"190","author":"Cairo","year":"2020","journal-title":"Br J Haematol"},{"key":"2025100314291469000_9.5.e002392.142","doi-asserted-by":"publisher","DOI":"10.26355\/eurrev_202004_20875"},{"key":"2025100314291469000_9.5.e002392.143","doi-asserted-by":"crossref","first-page":"108555","DOI":"10.1016\/j.clim.2020.108555","article-title":"Anti-Complement C5 therapy with eculizumab in three cases of critical COVID-19","volume":"219","author":"Laurence","year":"2020","journal-title":"Clin Immunol"},{"key":"2025100314291469000_9.5.e002392.144","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2020.108598"},{"key":"2025100314291469000_9.5.e002392.145","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2020-039951"},{"key":"2025100314291469000_9.5.e002392.146","doi-asserted-by":"crossref","DOI":"10.1111\/eci.13429","article-title":"Deciphering the COVID-19 cytokine storm: systematic review and meta-analysis","volume":"51","author":"Mulchandani","year":"2021","journal-title":"Eur J Clin Invest"},{"key":"2025100314291469000_9.5.e002392.147","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-03-564997"},{"key":"2025100314291469000_9.5.e002392.148","doi-asserted-by":"publisher","DOI":"10.14336\/AD.2020.0228"},{"key":"2025100314291469000_9.5.e002392.149","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2003138117"},{"key":"2025100314291469000_9.5.e002392.150","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.145"},{"key":"2025100314291469000_9.5.e002392.151","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s11899-016-0327-0","article-title":"T-Cell Receptor-Engineered cells for the treatment of hematologic malignancies","volume":"11","author":"Hossain","year":"2016","journal-title":"Curr Hematol Malig Rep"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2021-002392","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T21:29:35Z","timestamp":1759526975000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2021-002392"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":151,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2021,5,13]]},"published-print":{"date-parts":[[2021,5]]}},"alternative-id":["10.1136\/jitc-2021-002392"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2021-002392","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5]]}}}